The GLP-1 Compounding Crackdown, Explained

For research-use-only (RUO) educational purposes. For a couple of years, hundreds of thousands of people accessed semaglutide and tirzepatide not through brand-name pharmacies but through compounding pharmacies — at a fraction of the list price. Over 2025 and into 2026 that door largely closed, leaving a lot of people confused about what happened and what the remaining options actually are. This page explains the regulatory timeline plainly and lays out how to think about the landscape. It is education only — not legal advice, medical advice, dosing, or a guide to obtaining anything.

First, why compounding was ever allowed at scale

Under U.S. law, licensed compounding pharmacies can prepare a medication that is essentially a copy of an approved, commercially available drug only under specific exceptions. The biggest one is a declared drug shortage: when the FDA lists a drug as in shortage, compounders (both 503A pharmacies and 503B outsourcing facilities) are permitted to fill the gap.

That is the entire reason compounded GLP-1s existed in volume. When demand for semaglutide and tirzepatide outran supply, the FDA shortage listing created a legal window, and a large compounding market grew inside it — typically at $150–300/month versus a brand list price north of $1,000/month before insurance or coupons. The low price was real; so was the legal fragility, because the entire market was contingent on the shortage continuing.

The timeline: how the window closed

The window closed because the shortages were declared resolved — and the law’s logic followed automatically (timeline per FDA determinations and subsequent enforcement reporting):

• December 2024 — FDA declares the tirzepatide shortage resolved.
• February 2025 — FDA declares the semaglutide shortage resolved.
• Wind-down deadlines (which held and were enforced):
  • Tirzepatide: 503A pharmacies by Feb 19, 2025; 503B facilities by Mar 19, 2025.
  • Semaglutide: 503A pharmacies by Apr 22, 2025; 503B facilities by May 22, 2025.
• Legal challenge failed — the Outsourcing Facilities Association sued over both determinations; courts denied the preliminary injunctions and the deadlines stood.
• April 30, 2026 — the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B “bulks list,” a step that would block large-scale compounding more permanently.

Two precision points, because they’re where commentary usually goes wrong:

1. The April 30, 2026 bulks-list removal is a proposed rule — so the correct statement is that the FDA is moving to permanently close large-scale compounding of these molecules, not that it “has been permanently banned” in every form.
2. The closure is a consequence of the shortage ending, not a judgment that compounded product was inherently illegitimate. Many compounders operated lawfully inside the window; the window simply closed.

Where that leaves the landscape: three lanes

With the compounding lane narrowing, the field people describe generally reduces to three options. The point of laying them out is clarity, not endorsement — each has real trade-offs.

Lane 1 — Brand-name (FDA-approved)

What you get is the verified package: FDA-approved identity, purity, sterility, a known dose, the full clinical-trial evidence base, and ongoing safety surveillance (pharmacovigilance). What you give up is cost and access — list prices well above $1,000/month before insurance or manufacturer coupons, plus insurance hurdles. Notably, the brand supply chain is the counter-example to the sourcing concerns below: manufacturers are investing heavily in verified, increasingly domestic API production capacity.

Lane 2 — Compounding pharmacy (503A / 503B)

This is the lane that has largely closed for semaglutide and tirzepatide per the timeline above. Where any compounding of related products continues, it does so under tightening rules. The takeaway is structural: this lane existed because of a shortage, and the shortage is over.

Lane 3 — “Research-use-only” peptides

This is the grey-market lane, and it deserves the most careful, honest treatment because it is where the most people get hurt. Products here are sold labeled “for research use only / not for human use” — language that exists specifically to sit outside the FDA drug-approval framework. What that label means in practice:

• No verified identity, purity, sterility, or dose is guaranteed by any regulator.
• Documented quality problems are real, not hypothetical. Independent and manufacturer testing has reported impurities and mislabeling in unregulated copycat products — including a manufacturer’s own testing that found roughly one-third unknown impurities in a tested compounded sample, which became the basis for litigation. Poison-control reports related to GLP-1 dosing errors rose sharply over the same period as the grey market grew.
• The “for research only” framing does not change what a substance is — it changes what regulatory protections apply (essentially none on identity and quality).

We are describing risks, not issuing a recommendation. The honest summary of Lane 3 is: cheapest and easiest to access, and the only one of the three where nothing about the contents is independently guaranteed unless documented.

A note on sourcing concerns (kept at the category level)

A real and reported issue across the unregulated end of the market is active pharmaceutical ingredient (API) sourcing: a significant volume of peptide API has been shipped from overseas manufacturers, much of it on unregistered or uninspected facilities, and this has drawn formal U.S. government scrutiny — including a January 2026 congressional inquiry to several overseas biotech firms demanding their FDA registration and inspection histories.

The careful framing — the one supported by the public record — is that this is a category-level concern about the unregulated supply chain. It is not a basis for accusing any specific named pharmacy of using any specific source; that link requires a per-company citation that generally isn’t public. The lesson is about the category: when a supply chain is unregulated, you cannot assume where the material came from or how it was made.

The throughline: this is why verification exists

Strip away the regulatory detail and the entire crackdown points at one principle. The compounding window was a regulated, documented lane; what often replaces it is an undocumented one. The single objective tool that survives across all of this is independent verification of the actual material — not a label, not a vendor description, not a price.

For anything in the research-compound space, that means an independent, lot-specific Certificate of Analysis (COA) reporting mass-spectrometry identity and HPLC purity for the exact lot in hand. A label tells you what someone wants you to believe; a third-party COA reports what a lab actually measured. Our guides on how to read a peptide COA and how to spot a fake peptide vendor walk through exactly what to look for.

The short version

Compounded semaglutide and tirzepatide were legal mainly because of an FDA shortage; once the FDA declared the shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), the wind-down deadlines followed and the courts let them stand — and as of April 30, 2026 the FDA proposed removing these molecules from the 503B bulks list, moving to close large-scale compounding more permanently. That leaves three lanes — brand-name (verified but costly), compounding (largely closed), and grey-market RUO (cheapest, least verified) — each with honest trade-offs. The durable lesson under all of it is verification: when the regulated lane narrows, an independent COA is the only objective check on what a vial actually contains. None of this is legal advice, medical advice, or guidance on obtaining any product.

Research use only (RUO). The information above is provided strictly for educational and scientific purposes. It describes the regulatory record and published reports; some compounds referenced are approved medications discussed only at that level, and others are intended for laboratory research only. It is not legal advice, not medical advice, and not dosing, usage, or treatment guidance. Nothing here is a recommendation to acquire, administer, or use any compound. Always consult qualified professionals and applicable regulations.